➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Dow
Medtronic
Merck

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Cabotegravir

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Cabotegravir?

Cabotegravir is an investigational drug.

There have been 20 clinical trials for Cabotegravir. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are ViiV Healthcare, GlaxoSmithKline, and National Institute of Allergy and Infectious Diseases (NIAID).

There are twenty-nine US patents protecting this investigational drug and two hundred and thirty-one international patents.

Recent Clinical Trials for Cabotegravir
TitleSponsorPhase
A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesJanssen PharmaceuticalsPhase 3
A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesViiV HealthcarePhase 3
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsViiV HealthcarePhase 1

See all Cabotegravir clinical trials

Clinical Trial Summary for Cabotegravir

Top disease conditions for Cabotegravir
Top clinical trial sponsors for Cabotegravir

See all Cabotegravir clinical trials

US Patents for Cabotegravir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cabotegravir   Start Trial Substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives ViiV Healthcare Company (Wilmington, DE)   Start Trial
Cabotegravir   Start Trial Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives ViiV Healthcare Company (Wilmington, DE)   Start Trial
Cabotegravir   Start Trial Processes for preparing dolutegravir and cabotegravir and analogues thereof Lek Pharmaceuticals d.d. (Ljubljana, SI)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Dow
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.